[Metabolic consequences of a 6-hour interruption of a continuous subcutaneous insulin infusion pump in insulin-dependent diabetic patients].
D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000378:metabolism; D016883:Diabetic Ketoacidosis / Q000209:etiology; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D005934:Glucagon / Q000097:blood; D006801:Humans; D006885:Hydroxybutyrates / Q000097:blood; D007330:Insulin Antibodies / Q000032:analysis; D007332:Insulin Infusion Systems; D008297:Male; D015282:Octreotide; D012307:Risk Factors; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives; D013997:Time Factors
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D006885:Hydroxybutyrates; D007330:Insulin Antibodies; D013004:Somatostatin; D005934:Glucagon; D015282:Octreotide
Conséquences métaboliques de l'interruption pendant 6 heures d'une pompe à perfusion continue sous-cutanée d'insuline chez le patient diabétique insulinodépendant.